CareDx to Acquire Naveris, Expanding Oncology Diagnostics

CareDx ( (CDNA) ) has shared an announcement.

On April 28, 2026, CareDx agreed to acquire circulating tumor DNA specialist Naveris for $160 million in cash plus up to $100 million in revenue-based earnouts, with Naveris to become a wholly owned subsidiary subject to standard regulatory and closing conditions. The same day, the company also posted an updated corporate presentation and disclosed that the merger agreement includes customary termination rights and an outside closing date of October 28, 2026.

On April 24, 2026, CareDx’s board authorized a new $100 million common stock repurchase program to run for up to 24 months from April 30, 2026, funded with existing cash and future cash flows and separate from a prior $50 million authorization. In its first-quarter 2026 results for the period ended March 31, 2026, CareDx reported revenue of $118 million, up 39% year-on-year, returned to GAAP profitability with $3 million of net income and $19 million of adjusted EBITDA, and raised its 2026 revenue and adjusted EBITDA guidance on the back of strong growth in testing services and patient and digital solutions.

The company highlighted a strategic shift with a definitive agreement to sell its Lab Products business to Eurobio Scientific for $170 million, while doubling down on core transplant services and platforms such as its new AI-powered VANTx clinical data and analytics offering. Operationally, CareDx pointed to record cash collections, expanded Epic Aura integrations at transplant centers and a heavy scientific presence at major transplant conferences as reinforcing its competitive position in the transplant diagnostics and digital health ecosystem.

The most recent analyst rating on (CDNA) stock is a Hold with a $25.00 price target. To see the full list of analyst forecasts on CareDx stock, see the CDNA Stock Forecast page.

Spark’s Take on CDNA Stock

According to Spark, TipRanks’ AI Analyst, CDNA is a Neutral.

CDNA’s score is driven primarily by improving cash generation and a conservative balance sheet, but is held back by inconsistent profitability and uncertainty in reported 2025 gross profit/margin. Technical indicators are neutral-to-soft, and valuation is penalized by the negative P/E and lack of dividend data. Earnings call guidance is constructive with double-digit revenue growth and margin/EBITDA targets, though reimbursement and investment headwinds remain key risks.

To see Spark’s full report on CDNA stock, click here.

More about CareDx

CareDx, Inc., listed on Nasdaq as CDNA and branded as The Transplant Company, is a precision medicine player focused on improving outcomes for organ transplant patients. The company offers non-invasive molecular tests for heart, kidney and lung transplants, lab products, digital health technologies and patient support solutions, and is a leading provider of genomics-based information in the transplant market.

Its integrated portfolio targets transplant centers, clinicians and patients across the transplant journey, from pre-transplant evaluation through long-term graft monitoring and medication management. CareDx increasingly emphasizes high-margin testing services and digital solutions as it optimizes its portfolio and refines its operating model around core transplant-focused offerings.

Average Trading Volume: 677,416

Technical Sentiment Signal: Buy

Current Market Cap: $1.09B

Learn more about CDNA stock on TipRanks’ Stock Analysis page.